|
[1] FRIEDRICH-RUST M,THEOBALD J,ZEUZEM S,et al.Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic Hepatitis C[J].Viral Hepatol,2009,16(3):168-177.
|
|
[2] VEZALI E,ELEFSINIOTIS L,MIHAS C,et al.Thyroid dysfunction in patients with chronic hepatitis C:virus-or therapy-related?[J].J Gastroenterol Hepatol,2009,24(6):1024-1029.
|
|
[3] VASILIADIS T,ANAGNOSTIS P,NALMPANTIDIS G,et al.Thyroid dysfunction and long-term outcome during and after interferon-alpha therapy in patients with chronic hepatitis C[J].Ann Acad Med Singapore,2011,40(9):394-400.
|
|
[4]MENCONI F,HASHAM A,TOMER Y.Environmental triggers of thyroiditis:hepatitis C and interferon-α[J].J Endocrinol Invest,2011,34(1):78-84.
|
|
[5]ZHOU M,SUO YJ.A comparative study on standardized131I therapy in patients with Grave’s hyperthyroidism at different age ranges[J].J Clin Exp Med,2015,14(21):1798-1801.(in Chinese)周敏,索艳君.标准化131I治疗不同年龄段Grave’s甲亢的对比研究[J].临床和实验医学杂志,2015,14(21):1798-1801.
|
|
[6]HU B,SHI LH,TANG CB,et al.Study on the pathogen of postcholecystectomy syndrome non-induction by comcretion and tumor and the measurement of prevention and cure[J].N Chin Coal Med Coll,2005,7(1):11-12.(in Chinese)胡兵,石丽红,唐采白,等.非结石及肿瘤因素胆囊切除术后综合征的病因及防治[J].华北煤炭医学院学报,2005,7(1):11-12.
|
|
[7]JIANG NY,KUANG AR,TAN J,et al.Interpretation of experts consensus on131I therapy of Graves’s hyperthyroidism(2010)[J].Chin J Nucl Med,2010,30(5):346-351.(in Chinese)蒋宁一,匡安仁,谭建,等.131I治疗Graves甲亢专家共识(2010年)[J].中华核医学杂志,2010,30(5):346-351.
|
|
[8] TRAN HA,ATTIA JR,JONES TL,et al.Thyroid disease is a favorable prognostic factor in achieving sustained virologic response in chronic hepatitis C under going combination therapy:a nested case control study[J].BMC Endocr Disord,2011,11(1):10.
|
DownLoad: